Variable (mean doses in Gy) | Univariate | Multivariate | ||
---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
Contralateral submandibular gland dose | 0.97 (0.95–0.98) | <0.0001 | 0.98 (0.95–1.00) | 0.052 |
Middle pharyngeal constrictor dose | 0.92 (0.88–0.96) | 0.0002 | 0.95 (0.89–1.02) | 0.18 |
Superior pharyngeal constrictor dose | 0.95 (0.92–0.98) | 0.003 | 0.98 (0.93–1.03) | 0.38 |
Glottic/supraglottic larynx dose | 0.97 (0.94–0.99) | 0.007 | 1.02 (0.98–1.07) | 0.40 |
Esophageal inlet muscles dose | 0.98 (0.97–1.00) | 0.03 | 0.99 (0.97–1.01) | 0.39 |
Oral cavity dose | 0.97 (0.95–0.99) | 0.03 | 1.00 (0.97–1.04) | 0.86 |
Inferior pharyngeal constrictor dose | 0.98 (0.96–1.00) | 0.09 | ||
T4 tumor stage | 0.69 (0.42–1.15) | 0.16 | ||
Parotid glands mean dose | 0.98 (0.94–1.02) | 0.24 | ||
Bilateral nodal involvement | 0.77 (0.47–1.27) | 0.31 | ||
Cricopharyngeal muscle dose | 0.99 (0.97–1.01) | 0.34 | ||
Age | 1.00 (0.97–1.03) | 0.96 |